Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.

Abstract

PURPOSE To evaluate the efficacy of a combination of capecitabine, oxaliplatin, and radiotherapy (RT) in the neoadjuvant treatment of Stage II and III rectal cancers. METHODS Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT. Oxaliplatin was given intravenously at 50 mg/m(2) once weekly five times starting… (More)
DOI: 10.1016/j.ijrobp.2008.01.020

Topics

Cite this paper

@article{Fakih2008PhaseIS, title={Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.}, author={Marwan G. Fakih and Kelli M Bullarddunn and Gary Yang and Lakshmi Pendyala and K{\'a}roly T{\'o}th and Chris Andrews and Youcef M. Rustum and Mary Ellen Ross and Charles LeVea and Ajithkumar Puthillath and Young-Mee Park and Ashwani Rajput}, journal={International journal of radiation oncology, biology, physics}, year={2008}, volume={72 3}, pages={650-7} }